Business
ARIUS announces fourth quarter and year-end fiscal 2007 financial results
TORONTO, Jan. 29 /CNW/ - ARIUS Research Inc., (TSX: ARI), a biotechnology company discovering and...
About this update from Affinity Metals Corp
[{"type":"text","content":"\n\n\n\nTORONTO, Jan. 29 /CNW/ - ARIUS Research Inc., (TSX: ARI), a biotechnology\ncompany discovering and developing the next wave of antibody therapeutics,\ntoday announced its financial and operational results for the fourth quarter\nand fiscal year, ended November 30, 2007.\n\n\n"Fiscal 2007 was a critical year in our development, highlighted by the\nsignificant advancement we made with the pre-IND programs for our lead drug\ncandidates, our CD44 Cancer Stem Cell Program, our Trop-2 Signal Transduction\nProgram, our CD59 Complement Inhibitor Program and our CD9 Cancer Stem Cell\nProgram. The majority of our programs target cancer stem cells, an area that\ncancer researchers are particularly excited about as cancer stem cells have\nbeen implicated as the key cells responsible for the growth and spread of\ncancer," said Dr. David Young, President and CEO. "Building on this momentum,\nfiscal 2008 will be a pivotal year for us as we transition from a pre-clinical\nto a clinical company with the mission of moving one or more of our lead\nproducts into human clinical trials."\n\n\nProgram Updates:\n\nCD44 Cancer Stem Cell Program\n\n- Announced positive findings demonstrating no dose-limiting toxic\n effects of ARIUS' lead therapeutic, ARH460-16-2, at doses up to\n 95 mg/kg in a dose-ranging pilot toxicology study in a non-human\n primate model.\n- Achieved significant and potent tumor growth inhibitory activity in\n in vivo animal models of breast, prostate, liver, and AML cancers.\n- Engaged the manufacturer Avid Bioservices to produce ARIUS' lead\n anti-CD44 MAb under Current Good Manufacturing Practices ("cGMP") for\n human clinical trials. Cell line producing the humanized anti-CD44\n antibody was successfully transferred to Avid.\n- Presented key data at AACR, ASCO, ASCO's Breast Cancer Symposium,\n and AACR-EORTC.\n- Met with FDA to discuss plans for the upcoming IND submission.\n- Prepared to file a Phase I IND application and begin human clinical\n trials for the CD44 Cancer Stem Cell program in 2008.\n\nTrop-2 Signal Transduction Program\n\n- Announced positive findings demonstrating a significant anti-tumor\n effect of the lead anti-Trop-2 antibody in animal models of human\n pancreatic cancer, inhibiting tumor growth by up to 100 percent.\n- Discovered that ARIUS' Trop-2 antibody inhibits ...